HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carteaux, J. P. Articles by Hadvary, P. Search for Related Content PubMed PubMed Citation Articles by Carteaux, J. P. Articles by Hadvary, P.

The Journal of Thoracic and Cardiovascular Surgery, Vol 106, 834-841, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass

JP Carteaux, S Roux, H Kuhn, T Tschopp, V Colombo and P Hadvary
Pharma Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Extensive contact between blood and artificial surfaces causes platelet activation and depletion. The aim of the study was to test the efficacy of Ro 44-9883, a new nonpeptide, reversible, glycoprotein IIb/IIIa antagonist in preventing platelet count drop in dogs undergoing cardiopulmonary bypass during 2 hours. Twenty-two heparinized dogs were divided into three groups, one control group (n = 9) not treated, one group treated with a low dose of Ro 44-9883 (145 micrograms/kg intravenously, n = 6), and one group treated with a high dose of Ro 44- 9883 (870 micrograms/kg intravenously, n = 7). In the control group, platelet counts declined to 53% +/- 15% of initial levels at the start of cardiopulmonary bypass and remained lower than 80% of initial levels during follow-up. Platelet count drop was completely prevented in the Ro 44-9883 high-dose group, whereas it was only partially prevented in the low-dose group. Blood loss was similar in the three groups despite the fact that bleeding times were longer in the Ro 44-9883 high-dose group than in the control group. We conclude that Ro 44-9883, together with heparin as a standard anticoagulant, is highly effective in preventing platelet count drop during cardiopulmonary bypass without causing excessive bleeding.

This article has been cited by other articles:

				S. Tabata, S. Yamaguchi, H. Nagamine, S. Tomita, S. Arai, H. Takemura, and G. Watanabe Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 289 - 293. [Abstract] [Full Text] [PDF]

				A. Navdaev and K. J. Clemetson Glycoprotein Ib Cross-linking/Ligation on Echicetin-coated Surfaces or Echicetin-IgMkappa in Stirred Suspension Activates Platelets by Cytoskeleton Modulated Calcium Release J. Biol. Chem., November 22, 2002; 277(48): 45928 - 45934. [Abstract] [Full Text] [PDF]

				J. A. Hyde, J. A Chinn, and T. R Graham Platelets and cardiopulmonary bypass Perfusion, December 1, 1998; 13(6): 389 - 407. [PDF]

				M. Nakamura, C. F. Toombs, I. G. Duarte, R. S. Ronson, L. S. Schmarkey, S. L. Katzmark, J. Robinson, D. L. Dillehay, J. Vinten-Johansen, and R. A. Guyton Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia Ann. Thorac. Surg., October 1, 1998; 66(4): 1216 - 1223. [Abstract] [Full Text] [PDF]

				A. Bernabei, N. Gikakis, M. A. Kowalska, S. Niewiarowski, and L. H. Edmunds Jr Iloprost and Echistatin Protect Platelets During Simulated Extracorporeal Circulation Ann. Thorac. Surg., January 1, 1995; 59(1): 149 - 153. [Abstract] [Full Text]